<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">121619</article-id><article-id pub-id-type="doi">10.23868/gc121619</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Experience of Samara hematopoetic cells donor registry</article-title><trans-title-group xml:lang="ru"><trans-title>Опыт работы Самарского регистра доноров кроветворных клеток</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tyumina</surname><given-names>O. V</given-names></name><name xml:lang="ru"><surname>Тюмина</surname><given-names>О. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Klyuchnikov</surname><given-names>D. Y</given-names></name><name xml:lang="ru"><surname>Ключников</surname><given-names>Д. Ю</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Volchkov</surname><given-names>S. E</given-names></name><name xml:lang="ru"><surname>Волчков</surname><given-names>С. Е</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Trusova</surname><given-names>L. M</given-names></name><name xml:lang="ru"><surname>Трусова</surname><given-names>Л. М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Clinical Centre of Cell Technologies, Samara</institution></aff><aff><institution xml:lang="ru">Клинический центр клеточных технологий, Самара</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2013</year></pub-date><volume>8</volume><issue>2</issue><issue-title xml:lang="en">VOL 8, NO2 (2013)</issue-title><issue-title xml:lang="ru">ТОМ 8, №2 (2013)</issue-title><fpage>75</fpage><lpage>78</lpage><history><date date-type="received" iso-8601-date="2023-01-11"><day>11</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, Эко-Вектор</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/121619">https://genescells.ru/2313-1829/article/view/121619</self-uri><abstract xml:lang="en"><p>Transplantation of allogenic hematopoietic stem cells used for treatment of oncological and immune diseases during the late 1970s. Despite of that the matched donor search is the main problem in this field as before. To resolve this problem the bone marrow donor registries were established around the world. In 2010 Bone marrow donor registry (BMDR) was established in Clinical Centre of Cell Technologies. BMDR includes adult donors from many regions of Russia and cord blood units (CBUs) from Samara cord blood bank. At the present day, there are more than 5000 CBUs and 5000 donors. During the work of the registry 44 CBUs were handed to Russian and international transplant centers. In according with received results, the survival rate was about 65%. In relation with increase of oncohematological diseases in Russia the development of national bone marrow donor registry is extremely important.</p></abstract><trans-abstract xml:lang="ru"><p>Трансплантация аллогенных гемопоэтических стволовых клеток костного мозга и пуповинной крови применяется для лечения онкологических и иммунных заболеваний в мировой практике со второй половины прошлого века, но, несмотря на это, по-прежнему главной проблемой остается поиск совместимого донора. Для решения этой проблемы по всему миру были созданы регистры потенциальных доноров кроветворных клеток, включающие в свой состав банки пуповинной крови. В 2010 г. в Самаре на базе ГБУЗСО «Клинический центр клеточных технологий» был организован регистр потенциальных доноров кроветворных клеток. В его состав вошли единицы пуповинной крови из Самарского банка пуповинной крови и доноры кроветворных клеток из нескольких областей Российской Федерации. На сегодняшний день в составе регистра насчитывается более 5000 единиц пуповинной крови и 5000 потенциальных доноров кроветворных клеток. За время работы регистра из Самарского банка 44 единицы пуповинной крови были переданы в Российские и международные трансплантационные центры для проведения неродственных трансплантаций. По полученным результатам общая выживаемость пациентов после трансплантации кроветворных клеток пуповинной крови составила 65%. В связи с ростом он-когематологических заболеваний в РФ очень остро стоит вопрос о создании единого национального регистра доноров кроветворных клеток.</p></trans-abstract><kwd-group xml:lang="en"><kwd>hematopoietic stem cells</kwd><kwd>transplantation</kwd><kwd>bone marrow donor registry</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гемопоэтические стволовые клетки</kwd><kwd>трансплантация</kwd><kwd>регистры доноров костного мозга</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Gluckman E., Broxmeyer H.A., Auerbach A.D. et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. New Eng. J. Med. 1989; 321(17): 1174-78.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Donnal T.E. Bone Marrow Transplantation — past, present and future. Nobel Lecture 1990.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>http://bmdw.org/fileadmin/Press_Releases/Press_release_final.pdf</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>http://www.worldmarrow.org/fileadmin/Committees/STDC/20120101-STDC-wMDA_Standards.pdf</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>http://hla.alleles.org/nomenclature/stats.html</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>http://www.perepis-2010.ru/results_of_the_census/tab5.xls</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Maiers M., Gragert L., Klitz W. High-resolution HLA alleles and haplotypes in the United States population. Hum. Immunol. 2007; 68(9): 779-88.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Ashfaq K., Yahaya I., Hyde C. et al. Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technol. Assess 2010; 14(54): 11-30.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Cornelissen J.J., van Putten W.L., Verdonck L.F. et al. Results of a HOVON/SAKK donor versus no-donor analysis of фопролиферативный синдром (1), первичный семейный гемофагоцитарный лимфогистиоцитоз (1), первичный иммунодефицит (1) синдром Вискотта -Олдридча (1), синдром «голых» лимфоцитов (2); все пациенты высокой группы риска.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Yanada M., Matsuo K., Suzuki T. et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006; 106(12): 2657-63.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Goldstone A.H., Richards S.M., Lazarus H.M. et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial. Blood ; 111(4): 1827-33.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Vey N., Thomas X., Picard C., Kovascovicz T. et al. Allogeneic stem cell transplantation improves the outcome of adults with t (1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia 2006 ; 20(12): 2155-61.</mixed-citation></ref></ref-list></back></article>
